You are now leaving GSK Malta Health Portal

You are about to leave a GSK Website. By clicking this link, you will be taken to an external website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on this site. If you do not wish to leave this website, click on “Go Back” below:


Go back

Date of preparation: March 2018

Introducing Relvar Ellipta

Relvar Ellipta is an ICS/LABA combination for the treatment of asthma and COPD. 1 Relvar is the only ICS/LABA which delivers 24 hours of continuous efficacy from just one daily dose.

Find out more

Your FAQs answered

Frequently asked questions on Relvar Ellipta for asthma and COPD

See FAQs


  1. Relvar Ellipta Summary of Product Characteristics, GlaxoSmithKline.

Relvar and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies